Why the study?
Does the HER2 655 A>G polymorphism predict trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients?
Does the HER2 655 A>G polymorphism predict trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients?
The HER2 655 A>G polymorphism serves as a significant genetic marker for increased risk of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.
Answers are grounded in this paper and cite their sources.
Supports HER2 655 A>G as marker for trastuzumab cardiotoxicity; hypothesis-generating, requires validation in larger cohorts.
BACKGROUND: The HER2 655 A>G genetic variant has recently been associated with trastuzumab-induced cardiotoxicity in HER2 breast cancer patients. Considering previous results, the aim of our study was to validate the role of this polymorphism as a predictor of the cardiac toxicity of trastuzumab in breast cancer patients. METHODS: Our study population was composed of 78 HER2 breast cancer patients receiving trastuzumab. The HER2 655 A>G (rs1136201) genetic variant was genotyped using TaqMan allelic discrimination technology. Patients were classified on the basis of the occurrence of cardiotoxic events or the absence of cardiotoxic events during 1 year after the first infusion. RESULTS: The HER2 655 A>G polymorphism was significantly associated with cardiotoxicity: AG versus AA [P=0.012, odds ratio (OR)=5.12, 95% confidence interval (CI) 1.43-18.36], AG+GG versus AA (P=0.01, OR=5.72, 95% CI 1.50-21.76), AG versus AA+GG (P=0.005, OR=7.17, 95% CI 1.82-28.29). A meta-analysis combining these data with the results from previous studies confirmed this association. CONCLUSION: Our results support the role of the HER2 655 A>G polymorphism as a genetic marker of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Peña et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: